300 Boston Scientific Way
Marlborough, Massachusetts 01752-1291
Phone: 15086834000
www.bostonscientific.com
Boston Scientific (NYSE: BSX ) has outperformed the market over the past 15 years by 1.31% on an annualized basis producing an average annual return of 10.62%. Currently, Boston Scientific has a market capitalization of $76.29 billion. Buying $100 In BSX: If … Full story available on Benzinga.com
NORTHAMPTON, MA / ACCESSWIRE / September 27, 2023 / At Boston Scientific, we strive to advance science for life, which includes inspiring the next generation of STEM professionals who will help sha…
NORTHAMPTON, MA / ACCESSWIRE / September 27, 2023 / At Boston Scientific, we strive to advance science for life, which includes inspiring the next generation of STEM professionals who will help shape the future of health care. Using a combination of …
''Mad Money'' host Jim Cramer weighs in on stocks including: Devon Energy, Fiverr, Transmedics, Boston Scientific, Paramount and Uranium Energy.
"Mad Money" host Jim Cramer rings the lightning round bell, which means he''s giving his answers to callers'' stock questions at rapid speed.
Boston Scientific executive sells $872,685 worth of company shares, following a pre-established trading plan. 17 insider trades reported in 3 months. SEC filing.
Needham increased the price target for CrowdStrike Holdings, Inc. (NASDAQ: CRWD ) from $200 to $215. Needham analyst Alex Henderson maintained a Buy rating. CrowdStrike shares fell 1% to close at $163.89 on Wednesday. Raymond James raised FedEx Corporation (NYSE: FDX ) price target from $270 to $279. Raymond James analyst Patrick Tyler Brown maintained an Outperform rating. FedEx shares rose 0.2% to close at $250.52 on Wednesday. HC Wainwright & Co. cut the price target for Atlas Lithium Corporation (NASDAQ: ATLX ) from $56 to $52. HC Wainwright & Co. analyst Heiko Ihle maintained a Buy rating. Atlas Lithium shares fell 2.2% to close at $25.01 on Wednesday. Needham increased the price target for Boston Scientific Corporation (NYSE: Full story available on Benzinga.com